These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7956639)

  • 1. Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study.
    Pozzilli P; Visalli N; Boccuni ML; Baroni MG; Buzzetti R; Fioriti E; Signore A; Cavallo MG; Andreani D; Lucentini L
    Diabetes Care; 1994 Aug; 17(8):897-900. PubMed ID: 7956639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
    Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D
    Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study).
    Pozzilli P; Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Romiti A; Giovannini C; Lucentini L; Matteoli MC; Crinò A; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Suppa M; Sulli N; De Mattia G; Faldetta MR
    Eur J Endocrinol; 1997 Sep; 137(3):234-9. PubMed ID: 9330586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group.
    Pozzilli P; Visalli N; Boccuni ML; Baroni MG; Buzzetti R; Fioriti E; Signore A; Cavallo MG; Andreani D; Lucentini L
    Diabet Med; 1994; 11(1):98-104. PubMed ID: 8181261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).
    Crinò A; Schiaffini R; Manfrini S; Mesturino C; Visalli N; Beretta Anguissola G; Suraci C; Pitocco D; Spera S; Corbi S; Matteoli MC; Patera IP; Manca Bitti ML; Bizzarri C; Pozzilli P;
    Eur J Endocrinol; 2004 May; 150(5):719-24. PubMed ID: 15132730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus.
    Chase HP; Butler-Simon N; Garg S; McDuffie M; Hoops SL; O'Brien D
    Diabetologia; 1990 Jul; 33(7):444-6. PubMed ID: 2144835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists.
    Pozzilli P; Browne PD; Kolb H
    Diabetes Care; 1996 Dec; 19(12):1357-63. PubMed ID: 8941464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus.
    Crinó A; Schiaffini R; Ciampalini P; Suraci MC; Manfrini S; Visalli N; Matteoli MC; Patera P; Buzzetti R; Guglielmi C; Spera S; Costanza F; Fioriti E; Pitocco D; Pozzilli P;
    J Pediatr Endocrinol Metab; 2005 Aug; 18(8):749-54. PubMed ID: 16200840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes.
    Vidal J; Fernández-Balsells M; Sesmilo G; Aguilera E; Casamitjana R; Gomis R; Conget I
    Diabetes Care; 2000 Mar; 23(3):360-4. PubMed ID: 10868866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.
    Pozzilli P; Pitocco D; Visalli N; Cavallo MG; Buzzetti R; Crinò A; Spera S; Suraci C; Multari G; Cervoni M; Manca Bitti ML; Matteoli MC; Marietti G; Ferrazzoli F; Cassone Faldetta MR; Giordano C; Sbriglia M; Sarugeri E; Ghirlanda G
    Diabetologia; 2000 Aug; 43(8):1000-4. PubMed ID: 10990077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.
    Schnell O; Eisfelder B; Standl E; Ziegler AG
    Diabetes; 1997 Oct; 46(10):1607-11. PubMed ID: 9313757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM.
    Elliott JF; Marlin KL; Couch RM
    Diabetes Care; 1998 Oct; 21(10):1691-3. PubMed ID: 9773732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI).
    Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Lucentini L; Matteoli MC; Crinò A; Corbi S; Spera S; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Sulli N; Cervoni M; De Mattia G; Faldetta MR; Boscherini B; Pozzilli P
    Diabetes Metab Res Rev; 1999; 15(3):181-5. PubMed ID: 10441040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
    Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
    Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients.
    Vague P; Picq R; Bernal M; Lassmann-Vague V; Vialettes B
    Diabetologia; 1989 May; 32(5):316-21. PubMed ID: 2526769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients.
    Mendola G; Casamitjana R; Gomis R
    Diabetologia; 1989 Mar; 32(3):160-2. PubMed ID: 2526767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
    Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
    Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural course of remission in IDDM during 1st yr after diagnosis.
    Martin S; Pawlowski B; Greulich B; Ziegler AG; Mandrup-Poulsen T; Mahon J
    Diabetes Care; 1992 Jan; 15(1):66-74. PubMed ID: 1737543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
    Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
    Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8).
    Pozzilli P; Crinò A; Schiaffini R; Manfrini S; Fioriti E; Coppolino G; Pitocco D; Visalli N; Corbi S; Spera S; Suraci C; Cervoni M; Matteoli MC; Patera IP; Ghirlanda G;
    Diabetes Technol Ther; 2003; 5(6):965-74. PubMed ID: 14709198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.